DOCSLIB.ORG

Pdf?Sfvrsn=A0138b77 2)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pdf?Sfvrsn=A0138b77 2) Peer-Reviewed Journal Tracking and Analyzing Disease Trends Pages 1645–1970 ® EDITOR-IN-CHIEF D. Peter Drotman ASSOCIATE EDITORS EDITORIAL BOARD Charles Ben Beard, Fort Collins, Colorado, USA Barry J. Beaty, Fort Collins, Colorado, USA Ermias Belay, Atlanta, Georgia, USA Martin J. Blaser, New York, New York, USA David M. Bell, Atlanta, Georgia, USA Andrea Boggild, Toronto, Ontario, Canada Sharon Bloom, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA Richard Bradbury, Melbourne, Australia Arturo Casadevall, New York, New York, USA Mary Brandt, Atlanta, Georgia, USA Kenneth G. Castro, Atlanta, Georgia, USA Corrie Brown, Athens, Georgia, USA Vincent Deubel, Shanghai, China Charles H. Calisher, Fort Collins, Colorado, USA Christian Drosten, Charité Berlin, Germany Benjamin J. Cowling, Hong Kong, China Anthony Fiore, Atlanta, Georgia, USA Michel Drancourt, Marseille, France Isaac Chun-Hai Fung, Statesboro, Georgia, USA Paul V. Effler, Perth, Australia Kathleen Gensheimer, College Park, Maryland, USA David O. Freedman, Birmingham, Alabama, USA Rachel Gorwitz, Atlanta, Georgia, USA Peter Gerner-Smidt, Atlanta, Georgia, USA Duane J. Gubler, Singapore Stephen Hadler, Atlanta, Georgia, USA Richard L. Guerrant, Charlottesville, Virginia, USA Matthew J. Kuehnert, Edison, New Jersey, USA Scott Halstead, Arlington, Virginia, USA Nina Marano, Atlanta, Georgia, USA David L. Heymann, London, UK Martin I. Meltzer, Atlanta, Georgia, USA Keith Klugman, Seattle, Washington, USA David Morens, Bethesda, Maryland, USA J. Glenn Morris, Jr., Gainesville, Florida, USA Takeshi Kurata, Tokyo, Japan Patrice Nordmann, Fribourg, Switzerland S.K. Lam, Kuala Lumpur, Malaysia Johann D.D. Pitout, Calgary, Alberta, Canada Stuart Levy, Boston, Massachusetts, USA Ann Powers, Fort Collins, Colorado, USA John S. Mackenzie, Perth, Australia Didier Raoult, Marseille, France John E. McGowan, Jr., Atlanta, Georgia, USA Pierre E. Rollin, Atlanta, Georgia, USA Jennifer H. McQuiston, Atlanta, Georgia, USA Frederic E. Shaw, Atlanta, Georgia, USA Tom Marrie, Halifax, Nova Scotia, Canada David H. Walker, Galveston, Texas, USA Nkuchia M. M’ikanatha, Harrisburg, Pennsylvania, USA J. Todd Weber, Atlanta, Georgia, USA Frederick A. Murphy, Bethesda, Maryland, USA J. Scott Weese, Guelph, Ontario, Canada Barbara E. Murray, Houston, Texas, USA Managing Editor Stephen M. Ostroff, Silver Spring, Maryland, USA Byron Breedlove, Atlanta, Georgia, USA Mario Raviglione, Milan, Italy and Geneva, Switzerland David Relman, Palo Alto, California, USA Copy Editors Deanna Altomara, Dana Dolan, Guenael R. Rodier, Saône-et-Loire, France Karen Foster, Thomas Gryczan, Amy Guinn, Connie Schmaljohn, Frederick, Maryland, USA Shannon O’Connor, Tony Pearson-Clarke, Jude Rutledge, Tom Schwan, Hamilton, Montana, USA P. Lynne Stockton, Deborah Wenger Rosemary Soave, New York, New York, USA Production Thomas Eheman, William Hale, Barbara Segal, P. Frederick Sparling, Chapel Hill, North Carolina, USA Reginald Tucker Robert Swanepoel, Pretoria, South Africa David E. Swayne, Athens, Georgia, USA Journal Administrator Susan Richardson Phillip Tarr, St. Louis, Missouri, USA Editorial Assistants Jane McLean Boggess, Kaylyssa Quinn Duc Vugia, Richmond, California, USA Communications/Social Media Heidi Floyd, Mary Edythe Wilson, Iowa City, Iowa, USA Sarah Logan Gregory Emerging Infectious Diseases is published monthly by the Centers for Disease Control Founding Editor and Prevention, 1600 Clifton Rd NE, Mailstop H16-2, Atlanta, GA 30329-4027, USA. Joseph E. McDade, Rome, Georgia, USA Telephone 404-639-1960; email, [email protected] The conclusions, findings, and opinions expressed by authors All material published in Emerging Infectious Diseases is in the contributing to this journal do not necessarily reflect the official public domain and may be used and reprinted without special position of the U.S. Department of Health and Human Services, permission; proper citation, however, is required. the Public Health Service, the Centers for Disease Control and Use of trade names is for identification only and does not imply Prevention, or the authors’ affiliated institutions. Use of trade names endorsement by the Public Health Service or by the U.S. Department is for identification only and does not imply endorsement by any of of Health and Human Services. the groups named above. EMERGING INFECTIOUS DISEASES is a registered service mark of the U.S. Department of Health & Human Services (HHS). Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 8, August 2020 Parasitic Infections August 2020 Investigation and Serologic Follow-Up of Contacts of Early Confirmed Case-Patient with COVID-19, Washington, USA V.T. Chu et al. 1671 Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March–April 2020 J. Ferguson et al. 1679 Tuberculosis in Internationally Displaced Children Resettling in Harris County, Texas, USA, 2010-2015 For TB testing in immigrant children, research supports using interferon-gamma release assays rather than tuberculin skin tests. G.S. Lamb et al. 1686 Epidemiology of Legionnaires’ Disease, Hong Kong, China, 2005–2015 Y.-H. Leung et al. 1695 Rise in Babesiosis Cases, Pennsylvania, USA, 2005–2018 D. Ingram, T. Crook 1703 On the Cover Research A. E. d’Audebard de baron de Férussac (1786–1836) and Alcide Dessalines d’ Orbigny (1802–1857). Plate 24 from Natural, General and Particular History of the Acetabuiferous Cephalopods Living (detail). Sporadic Creutzfeldt-Jakob Disease among Physicians, Germany, 1993–2018 About the Cover p. 1965 sCJD patients were significantly more likely than the general population to be physicians. P. Hermann et al. 1710 Synopses Analysis of MarketScan Data for Immunosuppressive Association of Dengue Virus and Leptospira Conditions and Hospitalizations for Acute Respiratory Co-Infections with Malaria Severity Illness, United States M. Patel et al. 1720 R. Mandage et al. 1645 CrAssphage as a Novel Tool to Detect Human US CDC Real-Time Reverse Transcription PCR Fecal Contamination on Environmental Panel for Detection of Severe Acute Respiratory Surfaces and Hands Syndrome Coronavirus 2 G.W. Park et al. 1731 X. Lu et al. 1654 Evaluating the Effectiveness of Social Distancing Coronavirus Disease Outbreak in Call Center, Interventions to Delay or Flatten the Epidemic South Korea Curve of Coronavirus Disease S.Y. Park et al. 1666 L. Matrajt, T. Leung 1740 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 8, August 2020 Population Genomic Structure and Recent Evolution of Plasmodium knowlesi, Peninsular Malaysia S.E. Hocking et al. 1749 Human Outbreak of Trichinellosis Caused by Trichinella papuae, Central Kampong Thom August 2020 Province, Cambodia Y. Caron et al. 1759 Disseminated Echinococcus multilocularis Increased Sensitivity of Plasmodium falciparum Infection without Liver Involvement in Child, to Artesunate/Amodiaquine Despite 14 Years as Canada, 2018 First-Line Malaria Treatment, Zanzibar J. Joyce et al. 1856 M. Msellem et al. 1767 Canine Dracunculus Nematode Infection, Factors Associated with Prescription of Toledo, Spain Antimicrobial Drugs for Dogs and Cats, I. Diekmann et al. 1860 United Kingdom, 2014–2016 Leishmania donovani with Atypical Cutaneous D.A. Singleton et al. 1778 Manifestations, Himachal Pradesh, India, Linezolid-Associated Neurologic Adverse 2014–2018 Events in Patients with Multidrug-Resistant L. Thakur et al. 1864 Tuberculosis, France Doxycycline and Sitafloxacin Combination M. Jaspard et al. 1792 Therapy for Treating Highly Resistant Naturally Acquired Human Plasmodium Mycoplasma genitalium cynomolgi and P. knowlesi Infections, D. Durukan et al. 1870 Malaysian Borneo Autochthonous Gnathostomiasis in Madagascar T. Nada Raja et al. 1801 A. Raharisoa et al. 1875 Presence of Segmented Flavivirus Infections in North America Genotypic Heterogeneity of Orientia A. Kumar et al. 1810 tsutsugamushi in Scrub Typhus Patients and Thrombocytopenia Syndrome Co-infection, Characterizing Norovirus Transmission from Myanmar Outbreak Data, United States A.M. Win et al. 1878 M.K. Steele et al. 1818 Leishmania infantum in US-Born Dog Dispatches M.E. de Almeida et al. 1882 Mother-to-Child Transmission of Andes Virus Imported Monkeypox, Singapore through Breast Milk, Chile S.E.F. Yong et al. 1826 M. Ferrés et al. 1885 Population-Based Estimates of Chronic Bertiella studeri Infection in Children, Sri Lanka Conditions Affecting Risk for Complications from A. Amarasinghe et al. 1889 Coronavirus Disease, United States Spread of Multidrug-Resistant Bacteria by Moth M.L. Adams et al. 1831 Flies from Hospital Waste Water System Prolonged Persistence of SARS-CoV-2 RNA T. Rupprecht et al. 1893 in Body Fluids Atypical Pathogenicity of Avian Influenza (H3N1) J. Sun et al. 1834 Virus Involved in Outbreak, Belgium, 2019 Prognostic Value of Leukocytosis and Lymphopenia M. Steensels et al. 1899 for Coronavirus Disease Severity In Vivo Observation of Trombiculosis with G. Huang et al. 1839 Fluorescence–Advanced Videodermatoscopy SARS-CoV-2 Phylogenetic Analysis, Lazio Region, A. Ramondetta et al. 1904 Italy, February–March 2020 Evolution and Antigenic Drift of Influenza (H7N9) B. Bartolini et al. 1842 Viruses, China, 2019 Plasma-Derived Extracellular Vesicles as Potential J. Zhang et al. 1906 Biomarkers in Heart Transplant Patient with Chronic Chagas Disease N. Cortes-Serra et al. 1846 Research Letters Increasing Malaria Parasite Clearance Time after Doubling Time of the COVID-19 Epidemic by Chloroquine
Load more

Recommended publications
  • Ibuprofen: Pharmacology, Therapeutics and Side Effects
    Ibuprofen: Pharmacology, Therapeutics and Side Effects K.D. Rainsford Ibuprofen: Pharmacology, Therapeutics and Side Effects K.D. Rainsford Biomedical Research Centre Sheffield Hallam University Sheffield United Kingdom ISBN 978 3 0348 0495 0 ISBN 978 3 0348 0496 7 (eBook) DOI 10.1007/978 3 0348 0496 7 Springer Heidelberg New York Dordrecht London Library of Congress Control Number: 2012951702 # Springer Basel 2012 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.
    [Show full text]
  • Pharmacological Evaluation of Novel Dimers of an Arylpropionic Acid Class of Non-Selective Cyclooxygenase Inhibitors
    Halimi et al Tropical Journal of Pharmaceutical Research February 2017; 16 (2): 327-336 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v16i2.10 Original Research Article Pharmacological evaluation of novel dimers of an arylpropionic acid class of non-selective cyclooxygenase inhibitors Syed Muhammad Ashhad Halimi1*, Muhammad Saeed1, Safiullah1 and Khalid Muhammed Khan2 1Department of Pharmacy, University of Peshawar, Peshawar 25120, 2H.E.J. International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi 75270, Pakistan *For correspondence: Email: [email protected]; Tel: +92 91 9216750; Fax: +92 91 9218318 Received: 4 August 2016 Revised accepted: 5 January 2017 Abstract Purpose: To explore and identify cyclooxygenase (COX) inhibitors with optimal potency and efficacy using an arylpropionic acid class of drugs as lead molecules. Methods: The selected lead molecules were dimerised through chemical processes (reflux condensation) and characterised in terms of structural properties using infrared, proton nuclear magnetic resonance, electron impact mass spectrometry, and elemental analysis techniques. The molecules were evaluated pharmacologically for acute toxicity and anti-inflammatory (carrageenan- induced paw oedema test), analgesic (acetic acid-induced writhing test in mice), and antipyretic (Brewer’s yeast-induced pyrexia test in mice) activities against control (normal saline) and relevant reference standard drugs. Docking analyses were also performed to assess possible protein–ligand interactions. Results: The test compounds were non-toxic at doses of 50, 100 and 150 mg/kg body weight, ip.
    [Show full text]
  • Ibuprofen Safety at the Golden Anniversary. a Commentary and Recent Developments Giustino Varrassi1,* , Joseph V
    Submitted: 08 November, 2020 Accepted: 17 November, 2020 Published: 08 March, 2021 DOI:10.22514/sv.2020.16.0097 EDITORIAL Ibuprofen safety at the golden anniversary. A commentary and recent developments Giustino Varrassi1;* , Joseph V. Pergolizzi2 1Paolo Procacci Foundation, Via Tacito 7, Abstract 00193, Roma, Italy Ibuprofen is a long lasting non-steroidal anti-inflammatory drugs (NSAIDs) and still 2NEMA Research, Inc., Naples, Florida, United States of America represents one of the most diffused analgesics around the world. It has an interesting story started over 50 years ago. In this short comment to an already published paper, *Correspondence the authors try to focus some specific important point. On top, they illustrate the recent, [email protected] confusing and fake assertion on the potentially dangerous influence that ibuprofen could (Giustino Varrassi) have, increasing the risk of Coronavirus infection. This is also better illustrated in a previously published paper, where the readers could find more clear responses to eventual doubts. Keywords NSAIDs; Ibuprofen; COVID-19; Side effects 1. Introduction pathologies or patients’ necessities, but it is indisputable that ibuprofen is safe, and has extremely well-known side effects, The passing of Stewart Adams (Fig. 1) inspired the publica- mainly gastro-intestinal, like any other drug of its class [5]. tion of an interesting paper on the “golden anniversary” of Compared to other OTC analgesics, ibuprofen showed a better ibuprofen [1], whose inventor had been the mentioned great safety profile in a recent study analyzing several medicines Pharmacist [2]. [6]. Also, in a meta-analysis comparing over 1,000 patients He had joined the Boots Pure Drug Co., Ltd.
    [Show full text]
  • COX-1 and COX-2 Enzymes Synthesize Prostaglandins and Are Teacher Emeritus, University of Wisconsin-Madison) Mentor: Dr
    COX-1 And COX-2 Enzymes Synthesize Prostaglandins and Are Teacher Emeritus, University of Wisconsin-Madison) Mentor: Dr. David Nelson (Professor of Biochemistry, University of Wisconsin- (Student, University of Wisconsin-Madison) Center for Inhibited by NSAIDS (Nonsteroidal Anti-inflammatory Drugs) BioMolecular Madison West High School: Audra Amasino, Yuting Deng, Samuel Huang, Iris Lee, Adeyinka Lesi, Yaoli Pu, and Peter Vander Velden Modeling Advisor: Gary Graper, Teacher Emeritus, University of Wisconsin-Madison Mentors: Dr. David Nelson, Professor of Biochemistry, and Basudeb Bhattacharyya, Student, University of Wisconsin-Madison Abstract Prostaglandin Hormone Synthases (COX-1 and COX-2) are enzymes that produce prostaglandins. Prostaglandins are (1) Structure (3) Cyclooxygenase Active Sites responsible for fever, pain, and inflammation, but also the (5) Drugs maintenance of the lining of the stomach and prevention of In the pictures below, the heme is orange, the ulceration. COX-1 is found mainly in the gastrointestinal lining, hydrophobic knob is yellow, and the amino acids in the The three drugs below are all nonsteroidal anti- and COX-2 at sites of inflammation. NSAIDS (Nonsteroidal anti- Cyclooxygenase active site are colored in CPK (red for inflammatory drugs (NSAIDS). The first two NSAIDS, inflammatory drugs) such as aspirin, ibuprofen, naproxen, and oxygen, blue for nitrogen, and gray for carbon). aspirin and ibuprofen, are called nonselective Cox flurbiprofen inhibit both COX-1 and COX-2, and are taken inhibitors since they affect both COX-1 and COX-2 regularly by over 33 million Americans for pain and substantially (note their high COX-2/COX-1 effect inflammation. Some 10%-50% of these users suffer ratios).
    [Show full text]
  • Chapter 4 Prevention of Trichinella Infection in the Domestic
    FAO/WHO/OIE Guidelines for the surveillance, management, prevention and control of trichinellosis Editors J. Dupouy-Camet & K.D. Murrell Published by: Food and Agriculture Organization of the United Nations (FAO) World Health Organization (WHO) World Organisation for Animal Health (OIE) The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations, of the World Health Organization and of the World Organisation for Animal Health concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The designations 'developed' and 'developing' economies are intended for statistical convenience and do not necessarily express a judgement about the stage reached by a particular country, territory or area in the development process. The views expressed herein are those of the authors and do not necessarily represent those of the Food and Agriculture Organization of the United Nations, of the World Health Organization and of the World Organisation for Animal Health. All the publications of the World Organisation for Animal Health (OIE) are protected by international copyright law. Extracts may be copied, reproduced, translated, adapted or published in journals, documents, books, electronic media and any other medium destined for the public, for information, educational or commercial purposes, provided prior written permission has been granted by the OIE. The views expressed in signed articles are solely the responsibility of the authors. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO, WHO or OIE in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • 208271Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208271Orig1s000 OTHER REVIEW(S) Reference ID: 3963792 Reference ID: 3963792 Reference ID: 3963792 Reference ID: 3963792 Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Medical Policy PATIENT LABELING REVIEW Date: June 22, 2016 To: Donna Griebel, MD Director Division of Gastroenterology and Inborn Errors Products (DGIEP) Through: LaShawn Griffiths, MSHS-PH, BSN, RN Associate Director for Patient Labeling Division of Medical Policy Programs (DMPP) Marcia Williams, PhD Team Leader, Patient Labeling Division of Medical Policy Programs (DMPP) From: Karen Dowdy, RN, BSN Patient Labeling Reviewer Division of Medical Policy Programs (DMPP) Meeta Patel, Pharm.D. Regulatory Review Officer Office of Prescription Drug Promotion (OPDP) Subject: Review of Patient Labeling: Medication Guide (MG) and Instructions for Use (IFU) Drug Name (established RELISTOR (methylnaltrexone bromide) name): Dosage Form and Route: tablets, for oral use injection, for subcutaneous use Application NDA 208271 Type/Number: Applicant: Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., with its affiliate, Valeant Pharmaceutical North America being the communicant Reference ID: 3949385 1 INTRODUCTION On June 19, 2015, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., with its affiliate, Valeant Pharmaceutical North America being the communicant, submitted for the Agency’s review 505(b)(1) New Drug Application (NDA) 208271 for RELISTOR (methylnaltrexone bromide) tablets. The proposed indication for RELISTOR tablets is for the treatment of opioid- induced constipation (OIC) in adult patients with chronic non-cancer pain. The Applicant cross-references all data contained in RELISTOR Subcutaneous Injection NDA 021964/S-010 approved for the treatment of OIC in adult patients with chronic non-cancer pain on September 29, 2014.
    [Show full text]
  • Parasitology JWST138-Fm JWST138-Gunn February 21, 2012 16:59 Printer Name: Yet to Come P1: OTA/XYZ P2: ABC
    JWST138-fm JWST138-Gunn February 21, 2012 16:59 Printer Name: Yet to Come P1: OTA/XYZ P2: ABC Parasitology JWST138-fm JWST138-Gunn February 21, 2012 16:59 Printer Name: Yet to Come P1: OTA/XYZ P2: ABC Parasitology An Integrated Approach Alan Gunn Liverpool John Moores University, Liverpool, UK Sarah J. Pitt University of Brighton, UK Brighton and Sussex University Hospitals NHS Trust, Brighton, UK A John Wiley & Sons, Ltd., Publication JWST138-fm JWST138-Gunn February 21, 2012 16:59 Printer Name: Yet to Come P1: OTA/XYZ P2: ABC This edition first published 2012 © 2012 by by John Wiley & Sons, Ltd Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered Office John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial Offices 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell. The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • The Selection and Use of Essential Medicines
    WHO Technical Report Series 958 THE SELECTION AND USE OF ESSENTIAL MEDICINES This report presents the recommendations of the WHO Expert THE SELECTION AND USE Committee responsible for updating the WHO Model List of Essential Medicines. The fi rst part contains a review of the OF ESSENTIAL MEDICINES report of the meeting of the Expert Subcommittee on the Selection and Use of Essential Medicines, held in October 2008. It also provides details of new applications for paediatric medicines and summarizes the Committee’s considerations and justifi cations for additions and changes to the Model List, including its recommendations. Part Two of the publication is the report of the second meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Annexes include the revised version of the WHO Model List of Essential Medicines (the 16th) and the revised version of the WHO Model List of Report of the WHO Expert Committee, 2009 Essential Medicines for Children (the 2nd). In addition there is a list of all the items on the Model List sorted according to their (including the 16th WHO Model List of Essential Medicines Anatomical Therapeutic Chemical (ATC) classifi cation codes. and the 2nd WHO Model List of Essential Medicines for Children) WHO Technical Report Series — 958 WHO Technical ISBN 978-92-4-120958-8 Geneva TTRS958cover.inddRS958cover.indd 1 110.06.100.06.10 008:328:32 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health.
    [Show full text]
  • Systematics and Epidemiology of Trichinella
    Systematics and Epidemiology of Trichinella Edoardo Pozio1 and K. Darwin Murrell2 1Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanita`, viale Regina Elena 299, 00161 Rome, Italy 2Danish Centre for Experimental Parasitology, Department of Veterinary Pathobiology, Royal Veterinary and Agricultural University, Frederiksberg, Denmark Abstract ...................................368 1. Introduction . ...............................368 1.1. Trichinella as a Model for Basic Research ..........370 1.2. History of Trichinella Taxonomy .................370 2. Advances in the Systematics of Trichinella .............373 2.1. Biochemical and Molecular Studies ...............374 2.2. The Polymerase Chain Reaction Era . ...........375 2.3. Current Methods for Trichinella spp. identification . .....376 3. The Taxonomy of the Genus ......................377 3.1. The Encapsulated Clade......................378 3.2. The Non-Encapsulated Clade ..................388 4. Phylogeny . ...............................392 5. Biogeography. ...............................393 6. Epidemiology . ...............................396 6.1. The Sylvatic Cycle .........................397 6.2. The Domestic Cycle ........................403 6.3. Trichinellosis in Humans......................408 7. A New Approach: Trichinella-free Areas or Farms. Is it Possible? . ...............................413 8. Concluding Remarks . .........................416 Acknowledgements . .........................417 References . ...............................417
    [Show full text]
  • The Vasculature of Nurse Cells Infected with Non-Encapsulated Trichinella Sp
    THE VASCULATURE OF NURSE CELLS INFECTED WITH NON-ENCAPSULATED TRICHINELLA SP THE VASCULATURE OF NURSE CELLS INFECTED WITH NON-ENCAPSULATED TRICHINELLA SPECIES Pathamet Khositharattanakool, Nimit Morakote, Pichart Uparanukraw Department of Parasitology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand Abstract. The vasculature surrounding the nurse cells of encapsulated Trichi- nella spiralis has been described previously. It has been postulated the function of these vessels is to support the growth of the parasite. We describe here for the first time the vasculature surrounding the nurse cells of non-encapsulated T. pseudospiralis and T. papuae. Similar to the vasculature of uninfected muscle cells, the vessels surrounding non-encapsulated Trichinella nurse cells are dense and branched longitudinally along the long axis of the muscle cells; they also appear to be similar in diameter. The netting pattern of enlarged vessels found around T. spiralis (encapsulated) nurse cells is not present in non-encapsulated Trichinella infections. The vessels surrounding non-encapsulated Trichinella nurse cells seem to exist prior to parasite invasion of the muscle cell. Keywords: Trichinella, nurse cell, vasculature INTRODUCTION and replacement by rough endoplasmic reticulum (Despommier, 1976; Chang Trichinella is an intracellular parasitic et al, 1988; Jasmer, 1993), enlargement and nematode that infects skeletal muscle. division of nurse cell nuclei (Chang et al, Infection occurs by ingesting meat con- 1988; Despommier, 1993; Jasmer, 1993), taminated with the infective stage of mitochondrial damage by vacuolation Trichinella larvae. After the larvae develop (Despommier, 1975), and formation of col- into adults in the host intestine, mating oc- lagen capsule surrounding the nurse cell curs and gravid females release newborn (Polvere et al, 1997).
    [Show full text]
  • Seguridad Gastrointestinal, Cardiovascular Y Renal
    © 2015 Sociedad de Gastroenterología del Perú Antiinflamatorios no esteroides: seguridad gastrointestinal, cardiovascular y renal Nonsteroidal antiinflammatory drugs: gastrointestinal and cardiovascular and renal safety Teodoro Oscanoa-Espinoza1a, Frank Lizaraso-Soto1a 1 Facultad de Medicina, Universidad San MartÍn de Porres. Lima, Perú. a Doctor en medicina Recibido: 16-05-2014; Aprobado: 28-09-2014 RESUMEN La selección de un medicamento específico perteneciente a una clase farmacológica es bajo criterios de eficacia, seguridad, costo y conveniencia. Los Antiinflamatorios No Esteroideos (AINEs) actualmente se constituyen en uno de los medicamentos más consumidos en el mundo, por lo tanto es de gran importancia la revisión de los aspectos de seguridad de este grupo farmacológico. El presente trabajo tiene el objetivo de analizar bajo las evidencias disponibles hasta la actualidad, la seguridad de los AINES con 3 criterios principales: gastrolesividad, cardiotoxicidad y nefrotoxicidad. DE REVISIÓN ARTÍCULOS Palabras clave: Antiinflamatorios no esteroideos; Reacciones adversas y efectos colaterales relacionados con medicamentos; Insuficiencia renal; hipertensión (fuente: DeCS BIREME). ABSTRACT The choice of a specific medication belonging to a drug class is under the criteria of efficacy, safety, cost and suitability. NSAIDs currently constitute one of the most consumed drugs in the world, so it is very important review of the safety aspects of this drug class. This review has the objective of analyze the safety of NSAIDs on 3 main criteria: gastrolesivity, cardiotoxicity and nephrotoxicity. Key words: Anti-inflammatory agents, non-steroidal; Drug-related side effects and adverse reactions; Renal insufficiency; hypertension (source: MeSH NLM). Introducción Hace 3 500 años Hipócrates prescribía el extracto y las hojas de corteza de sauce para tratar la fiebre e Los antiinflamatorios no esteroideos (AINEs), inflamación.
    [Show full text]
  • Ibuprofen: Pharmacology, Therapeutics and Side Effects
    Ibuprofen: Pharmacology, Therapeutics and Side Effects . K.D. Rainsford Ibuprofen: Pharmacology, Therapeutics and Side Effects K.D. Rainsford Biomedical Research Centre Sheffield Hallam University Sheffield United Kingdom ISBN 978-3-0348-0495-0 ISBN 978-3-0348-0496-7 (eBook) DOI 10.1007/978-3-0348-0496-7 Springer Heidelberg New York Dordrecht London Library of Congress Control Number: 2012951702 # Springer Basel 2012 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.
    [Show full text]